Work

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-130797

Authors: Fiona Brown, Yang Zhang, Claire Hinterschied, Alexander Prouty, Shelby Sloan, JoBeth Helmig-Mason, Ji Hyun Chung, Kris Vaddi, Selina Chen-Kiang, Maurizio Di Liberto, Lapo Alinari, Peggy Scherle, Rosa Lapalombella, Jihye Paik, Robert A Baiocchi

Institutions: The Ohio State University, Prelude Therapeutics Incorporated (United States), Weill Cornell Medicine, Cornell University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Language: English

Topic: Cancer-related gene regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2982869683

Cites:

Cited by: 4

Related to: 10